Wednesday, November 18, 2009
Incorrect Car Battery Ah
Celtura - Big Business after the swine flu?
fast-track approval - this is the new trend may emerge in vaccines Pandemrix Focetria and Celvapan. cost of long-term studies can be saved. We ended up pandemic! So now the fourth vaccine Celtura. 
SwissMedic Sun reported on 13 November 2009 by the approval of the new vaccine. "(...) Bern, 13 November 2009, the Swiss Agency for Therapeutic Products, Swissmedic has approved another vaccine against swine influenza A (H1N1) is this is Celtura the company Novartis.. With the approval by Swissmedic are thus in Switzerland now has three vaccines against the A (H1N1) flu. Unlike in October approved vaccines Focetria and Pandemrix the antigen component of Celtura not on the basis of eggs but on the basis of a cell culture produced. This production is novel and has been reviewed by Swiss Medic. was omitted (...) "
As with other vaccines, the manufacturer can provide no clear evidence of effect in the form of a health advantage over the non-vaccination as to appropriate long-term studies. Side effects were recorded in manufacturer-funded small studies only a few weeks. Medium - and long-term side effects, and those that occur less frequently were able, through these studies can not be detected
The production process:
Especially with this vaccine is the manufacturing process while coming in vaccines Pandemrix Focetria and Celvapan hens' eggs.. , is the company Novartis in the vaccine Celtura to a novel method which first came to the flu vaccine Optaflu used:
Pharmaceutical newspaper : (...) In Celtura it is an adjuvanted A (H1N1) cell culture-based vaccine. One dose contains 7.5 micrograms of antigen, which is obtained in MDCK cells (Madin-Darby canine kidney), an established cell line from canine kidney. In addition, the adjuvant MF59 has been added. (...) Will result
Celtura, as well Optaflu produced on the basis of MDCK cells derived from canine kidney. MDCK cells are permanent cell lines, they can continuously and share cancerous growth. They are virtually unlimited viable.
dissolved in animals MDCK cells from cancer
This confirmed the drug-Telegram from 12/2007
Optaflu the vaccine, based on the same manufacturing process. (...) Unlike the traditional virus cultivation in embryonated chicken eggs, the vaccine viruses for Optaflu in a permanent (immortal) cell line can be increased. The use of 1958 by Madin and Darby in the kidneys of a Cocker Spaniel produced *- MDCK cell line is to make vaccine production more flexible and independent of chicken eggs and increase the yield. This is particularly in the case of a flu pandemic as Vorteil.2 enters the company to new territory. In the MDCK cells are a tumorigenic cell line, which means the cells can form tumors in a host organism. The fewer cells in animals are needed for the more pronounced the tumorigenicity. Of the products used for Optaflu-MDCK cells reach ten, to form tumors in nude mice. They are therefore considered highly tumorigenic (...)
Conclusion.
shoot first then ask. Using the principle of population, a vaccine is injected, which can subsequently the tills ringing. Side effects? - Highly profitable!
Big Business by secondary damage!
The approval of a vaccine against swine flu - drive a disease, not nearly as bad as the seasonal flu by avoiding long-term studies, by the indulgence of hysteria and panic, the pharmaceutical industry gate or door open to a billion dollar business to the health of people in this world.
include cancer drugs in the pharmaceutical industry's most important growth market. The projections are for sales increase by 50 percent by 2013, then 85 billion dollars (55 billion €) aus. Ein Impfstoff der Krebs auslöst kommt hier gerade recht. Von den Verstärkerstoffen einmal ganz abgesehen!
Was noch fehlt? Der Aufruf zu Zwangsimpfungen und das Geschäft boomt!
Lesen Sie auch:
Zusatzstoffe von Celtura, offener Brief von Jane Bürgermeister
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment